FX Solutions, SAS. and FX Shoulder, Inc. to Merge into FX

Now One Global Brand with One Global Identity Focused on the Shoulder Arthroplasty Market

FX Solutions was founded in 2011 in Viriat, France, and there has always been a vision and passion to grow the portfolio to become a major global competitor. With its start in France, they quickly expanded their market presence throughout Europe.

In 2017, FX Solutions was acquired by Ekkio Capital (Paris, FR). This was the driving force to begin expansion into an extremely competitive US market. FX Shoulder USA was launched as a subsidiary of FX Solutions and quickly grew their footprint in the US Market. With many recent changes and innovations in the US, FX Shoulder has become one of the fastest growing and most innovative companies in its market segment. This was done by staying hyper-focused on shoulder arthroplasty—a market segment that continues to grow at an aggressive pace with constant innovation that allows surgeons even more solutions to care for patients.

“With a complete portfolio and with constant innovation, the time is now to join our two companies as one identity on the global stage,” said, Baptiste Martin, CEO of FX. “This will allow us to streamline our efforts and move as one team with one common goal—to grow our portfolio and market share globally with several key areas of opportunity.”

FX Shoulder USA, Inc. is the direct provider of FX Solutions shoulder replacement devices in the US. FX Solutions will continue to provide the portfolio and sales efforts worldwide (OUS). Both will now be branded as one company [FX] with a US Headquarters in Dallas, and a Global Headquarters in Viriat, France.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.